200 likes | 322 Views
WHO 3x5 Strategy Davidson Hamer, MD Center for International Health Boston U. School of Public Health Tufts University School of Medicine. Three by Five Initiative Access to HIV/AIDS Medicines. Goal is universal access to antiretroviral therapy as a human right
E N D
WHO 3x5 Strategy Davidson Hamer, MD Center for International Health Boston U. School of Public Health Tufts University School of Medicine
Three by Five InitiativeAccess to HIV/AIDS Medicines • Goal is universal access to antiretroviral therapy as a human right • Target is three million people on treatment by the end of 2005 • Treatment gap was declared a global health emergency Sept 22nd at UNGA
Pre-Treatment with ART Photo courtesy of Serena Koenig, Partners in Health
Post-Treatment with ART Photo courtesy of Serena Koenig Partners in Health
Pillar 1: WHO and Global Level Activities • Visible WHO leadership and commitment to urgent action to reach the goal of universal access to ART • Locate the rights-based 3x5 initiative within the broader development context • Support all national efforts whilst focusing WHO resources on high-burden and strategic countries to achieve maximal impact of 3x5 initiative • Align and mobilize partner support to achieve 3x5 target at global level • Member states, UNAIDS co-sponsors, other partners
Pillar 2: Country Support Efforts 5. Secure key elements required at the national level to deliver the 3x5 target as part of a comprehensive response to HIV/AIDS 6. Strengthen and support the renewal of health systems and national operational capacity for scaling up ART programs 7. Strengthen and build human capacity for scaling up ART 8. Expand capacity of communities to be fully involved in ART program activities • National Medicines Policy (Selection, procurement, regulation, supply chain management, rational use)
Pillar 3: Simplified, Standardized Tools 9. Simplify and standardize procedures to identify individuals in need of therapy and facilitate entry to ART programs • Rapid test-based approach 10. Simplify and standardize ARV therapy to facilitate adherence and enable rapid scale-up to be implemented • 4 First-line treatments • FDCs and blister packs 11. Simplify and standardize tools for tracking ART program performance including drug resistance surveillance • Standardized M&E Guidelines
Pillar 4: Effective, Reliable Supply of Medicines and Diagnostics 12. Support country access to, and efficient distribution of high quality, low cost medicines and diagnostics • Will utilize the newly established AIDS Medicines and Diagnostics Service (AMDS)
Three by Five Initiative AIDS Medicines and Diagnostics Service (AMDS)
AMDS Objectives • Ensure that the supply of quality commodities is never an obstacle to expanding treatment, care and support • Use improved commodity supply to: • Catalyze rapid expansion of treatment • Promote equity • Support prevention
AMDS Will Assist/Support a Country-Driven Process • Create information hub • Bring together strategic information from existing sources (ensure ease of access) • Develop new tools as needed (self or contracted) • Serve as “one-stop-shop” for specific support • Initiate and act as gateway for information and Technical Assistance by partners inside and outside WHO • Support operational staff • (Recruit), train and support dedicated procurement and supply chain management staff
What the AMDS Will Not Do • No procurement itself but • Support countries to buy/manage supplies • Direct to appropriate services • ARVs: PQ Procurement agencies • Diagnostics: WHO bulk procurement scheme • No repeat /duplicate effort • Use ongoing work, available expertise and information • No new structures MOH, NGO • No funding to purchase commodities
Challenges Facing the Three by Five Initiative • Funding shortage • Estimated need for project is $5.5 billion but only $2.3 billion secured • Only the UK, Sweden, and Spain have provided money thus far • Global fund money may not be available for: • Necessary technical support • Health systems development • Training and capacity strengthening
Challenges Facing Three by Five • Lack of international support • United States balking at supporting the project • Opposition by multinational pharmaceutical companies and others (?US government, FDA) to generic FDC • Optimal approach to integrate into other programs (e.g., PEPFAR, Global Fund)
Challenges Facing Three by Five • Development of effective programs for monitoring and managing serious drug toxicities • Nevirapine – Steven’s Johnson syndrome Fulminant hepatitis • Stavudine -- lipodystrophy, lactic acidosis • Need for second and third-line regimens • Increasing development and transmission of multidrug-resistant HIV
Acknowledgements • ICIUM organizers • Peter Graaf, WHO • Serena Koenig, PIH